AbbVie Current Ratio 2010-2022 | ABBV

Current and historical current ratio for AbbVie (ABBV) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. AbbVie current ratio for the three months ending June 30, 2022 was 0.84.
AbbVie Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $29.10B $34.47B 0.84
2022-03-31 $26.51B $32.52B 0.82
2021-12-31 $27.93B $35.19B 0.79
2021-09-30 $28.96B $28.53B 1.02
2021-06-30 $26.00B $28.68B 0.91
2021-03-31 $26.57B $31.95B 0.83
2020-12-31 $24.17B $28.66B 0.84
2020-09-30 $23.01B $24.18B 0.95
2020-06-30 $21.26B $24.65B 0.86
2020-03-31 $51.76B $16.47B 3.14
2019-12-31 $49.52B $15.59B 3.18
2019-09-30 $20.17B $17.49B 1.15
2019-06-30 $15.10B $16.94B 0.89
2019-03-31 $14.41B $13.90B 1.04
2018-12-31 $16.95B $17.24B 0.98
2018-09-30 $18.47B $15.39B 1.20
2018-06-30 $13.85B $17.22B 0.80
2018-03-31 $20.44B $17.06B 1.20
2017-12-31 $21.22B $16.64B 1.28
2017-09-30 $18.93B $13.03B 1.45
2017-06-30 $16.96B $12.26B 1.38
2017-03-31 $15.55B $8.84B 1.76
2016-12-31 $16.19B $9.78B 1.66
2016-09-30 $16.29B $9.10B 1.79
2016-06-30 $16.79B $9.27B 1.81
2016-03-31 $16.62B $10.66B 1.56
2015-12-31 $16.31B $10.89B 1.50
2015-09-30 $17.91B $8.81B 2.03
2015-06-30 $16.88B $11.26B 1.50
2015-03-31 $15.41B $11.05B 1.39
2014-12-31 $16.08B $11.39B 1.41
2014-09-30 $17.56B $6.64B 2.65
2014-06-30 $17.79B $6.32B 2.82
2014-03-31 $17.33B $6.22B 2.79
2013-12-31 $17.85B $6.88B 2.60
2013-09-30 $16.54B $6.88B 2.41
2013-06-30 $15.66B $6.81B 2.30
2013-03-31 $14.92B $6.77B 2.21
2012-12-31 $15.35B $6.78B 2.27
2012-09-30 $10.93B $5.37B 2.04
2012-06-30 $5.99B $4.84B 1.24
2012-03-31 $6.75B $5.52B 1.22
2011-12-31 $7.35B $5.90B 1.25
2011-09-30 $0.00B 0.00
2011-06-30 $0.00B 0.00
2011-03-31 $0.00B 0.00
2010-12-31 $8.22B $3.76B 2.19
2009-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $252.131B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $434.603B 16.55
Eli Lilly (LLY) United States $292.730B 37.12
Pfizer (PFE) United States $281.235B 8.24
Novo Nordisk (NVO) Denmark $243.269B 32.09
Merck (MRK) United States $230.579B 12.04
Novartis AG (NVS) Switzerland $189.576B 13.98